Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RHYTHM PHARMACEUTICALS, INC.
Report date October 10, 2017 · Filed October 10, 2017
Section 16 reporting ended · disclosed 2017-10-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe owner of record of the securities is Sutrepa SAS. Sutrepa SAS is controlled by Ipsen SA | 645,161 |
Reported balance
After 2017-10-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-10-10 · Conversion · Acquired 45,831 · Balance 645,161 F1: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectThe owner of record of the securities is Sutrepa SAS. Sutrepa SAS is controlled by Ipsen SA | 813,099 |
Reported balance
After 2017-10-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-10-10 · Conversion · Acquired 167,938 · Balance 813,099 F1: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectThe owner of record of the securities is Ipsen Pharma, S.A.S., which is controlled by Ipsen SA | 833,099 |
Reported balance
After 2017-10-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-10-10 · Purchase · Acquired 20,000 · Balance 833,099 |
| Series A-1 Junior Preferred StockSEC Table II · derivative / convertible security | IndirectThe owner of record of the securities is Sutrepa SAS.Sutrepa SAS is controlled by Ipsen SA | 0 |
Reported balance
After 2017-10-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-10 · Conversion · Disposed 45,831 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F2: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectThe owner of record of the securities is Sutrepa SAS.Sutrepa SAS is controlled by Ipsen SA | 0 |
Reported balance
After 2017-10-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-10 · Conversion · Disposed 167,938 · Balance 0 F1: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F2: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date.
F2: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 10, 2017 Filed Oct 10, 2017 16:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionSeries A Convertible Preferred Stock · Derivative | 167,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-061574 · a4.xml · derivative · entry 5 Ipsen, S.A. · CIK 0001370483 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · The owner of record of the securities is Sutrepa SAS.Sutrepa SAS is controlled by Ipsen SA Disclosed balance after: 0 Underlying: Common Stock · 167,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F2 · shares: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F2 · derivative.underlying_shares: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 16:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionSeries A-1 Junior Preferred Stock · Derivative | 45,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-061574 · a4.xml · derivative · entry 4 Ipsen, S.A. · CIK 0001370483 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · The owner of record of the securities is Sutrepa SAS.Sutrepa SAS is controlled by Ipsen SA Disclosed balance after: 0 Underlying: Common Stock · 45,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F2 · shares: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. F2 · derivative.underlying_shares: Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 16:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | PurchaseCommon Stock | 20,000 | $17.00 | $340,000.00 |
DisclosureSEC source: 0001104659-17-061574 · a4.xml · nonDerivative · entry 3 Ipsen, S.A. · CIK 0001370483 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · The owner of record of the securities is Ipsen Pharma, S.A.S., which is controlled by Ipsen SA Disclosed balance after: 833,099 Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 16:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionCommon Stock | 167,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-061574 · a4.xml · nonDerivative · entry 2 Ipsen, S.A. · CIK 0001370483 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · The owner of record of the securities is Sutrepa SAS. Sutrepa SAS is controlled by Ipsen SA Disclosed balance after: 813,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 16:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionCommon Stock | 45,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-061574 · a4.xml · nonDerivative · entry 1 Ipsen, S.A. · CIK 0001370483 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · The owner of record of the securities is Sutrepa SAS. Sutrepa SAS is controlled by Ipsen SA Disclosed balance after: 645,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.